恒瑞医药(600276.SH)：SHR-1918注射液药品上市许可申请获受理并纳入优先审评程序

Core Viewpoint - Heng Rui Medicine's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received a notice of acceptance from the National Medical Products Administration for its innovative drug SHR-1918 injection, which has been included in the priority review process [1] Group 1 - The drug SHR-1918 is intended for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH) [1]